Physician profile

Amy Priddle

Physician Assistant · Little Rock, AR

NPI 1225304801

$508.68

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$65.06

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Fresenius USA Marketing, INC. $118.34 2021-2024 Velphoro
Astrazeneca Pharmaceuticals Lp $112.28 2021-2022
Glaxosmithkline, LLC. $83.32 2021-2022
Vifor Pharma, INC. $62.76 2021
Amgen INC. $47.80 2022
Bayer Healthcare Pharmaceuticals INC. $25.17 2022
Opko Pharmaceuticals, LLC $20.85 2021
Novo Nordisk INC $19.52 2024 Rivfloza
Mallinckrodt Hospital Products INC. $18.64 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Amy Priddle

$508.68

in general payments reported 2019-2025

Years
2021-2024
Top company
Fresenius USA Marketing, INC.

https://glasscript.com/doctor/10573521/amy-priddle

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.